Tackling influenza with broadly neutralizing antibodies

Area of Science:

• Immunology and Virology
• Therapeutic Antibody Development

Background:

• Monoclonal antibodies have transformed treatments for cancer, autoimmunity, and inflammatory diseases.
• They are emerging as a promising therapeutic strategy for infectious diseases.
• Recent advancements enable isolation of human antibodies targeting highly variable influenza viruses.

Purpose of the Study:

• To provide a comprehensive overview of broadly reactive monoclonal antibodies against influenza viruses.
• To detail the specificity, antiviral, and immunological mechanisms of action.
• To summarize the clinical development of these antibodies.

Main Methods:

• Interrogation of the human antibody repertoire from influenza-immune individuals.
• Isolation and characterization of monoclonal antibodies.
• Review of preclinical and clinical development data.

Main Results:

• Identification of monoclonal antibodies with broad reactivity against influenza A and B viruses.
• Elucidation of diverse mechanisms of action, including direct viral neutralization and immune modulation.
• Progress in the clinical development of selected broadly reactive antibodies.

Conclusions:

• Broadly reactive monoclonal antibodies represent a significant advancement in influenza therapeutics.
• These antibodies demonstrate potential for broad protection against diverse influenza strains.
• Further clinical development is crucial for realizing their therapeutic potential.